Observational studyPLoS neglected tropical diseases2015
Outcome after Discontinuing Long-Term Benzimidazole Treatment in 11 Patients with Non-resectable Alveolar Echinococcosis with Negative FDG-PET/CT and Anti-EmII/3-10 Serology.
Observational study in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00658294 (Analysis of the Potentially Parasitocidal Effect of a Long Term Chemotherapy With Benzimidazoles in Patients With Inoperable Alveolar Echinococcosis Using PET-CT and EmII/3-10 Serology), which is not on this map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Analysis of the Potentially Parasitocidal Effect of a Long Term Chemotherapy With Benzimidazoles in Patients With Inoperable Alveolar Echinococcosis Using PET-CT and EmII/3-10 Serology
Who cites it
36 citing papers in PubMed, 76 citations in OpenAlex.
- Postoperative CT-derived spleen volumetry for recurrence risk stratification after curative-intent surgery for hepatic alveolar echinococcosis.Infection · 2026Article
- Thymol and Carvacrol Against Echinococcus spp.: Experimental Evidence, Mechanistic Insights, and Translational Perspectives.Acta parasitologica · 2026Review
- Whole-body dynamic FDG-PET/CT parametric imaging in alveolar echinococcosis.Annals of nuclear medicine · 2026Article
- Diagnosis of hepatic alveolar echinococcosis:18F-FDG-PET activity compared to the Echinococcus multilocularis Ulm Ultrasound Classification.Nuklearmedizin. Nuclear medicine · 2026Article
- Hepatobiliary alveolar echinococcosis treated with delayed resection following percutaneous drainage.Annals of hepato-biliary-pancreatic surgery · 2025Article
- Sonographic double patterns in hepatic alveolar echinococcosis according to the echinococcosis multilocularis ultrasound classification.Parasitology research · 2025Article
- Comprehensive Survival Analysis of Alveolar Echinococcosis Patients, University Hospital Zurich, Zurich, Switzerland, 1973-2022.Emerging infectious diseases · 2025Article
- Advances in Novel Diagnostic Techniques for Alveolar Echinococcosis.Diagnostics (Basel, Switzerland) · 2025Review
- Extracts and Terpenoids fromMolecules (Basel, Switzerland) · 2024Article
- Clinical value of the semi-quantitative parameters ofBMC medical imaging · 2024Article
- Chemotherapy for the treatment of alveolar echinococcosis: Where are we?Parasite (Paris, France) · 2024Review
- Article
- Article
- Monoclonal antibody-based localization of major diagnostic antigens in metacestode tissue, excretory/secretory products, and extracellular vesicles ofFrontiers in cellular and infection microbiology · 2023Article
- Targeting Echinococcus multilocularis PIM kinase for improving anti-parasitic chemotherapy.PLoS neglected tropical diseases · 2022Article
- Prediction of benzimidazole therapy duration with PET/CT in inoperable patients with alveolar echinococcosis.Scientific reports · 2022Article
- Initial Risk Assessment in Patients with Alveolar Echinococcosis-Results from a Retrospective Cohort Study.Pathogens (Basel, Switzerland) · 2022Article
- Serological Assays for Alveolar and Cystic Echinococcosis-A Comparative Multi-Test Study in Switzerland and Kyrgyzstan.Pathogens (Basel, Switzerland) · 2022Article
- Role of the radiologist in the diagnosis and management of the two forms of hepatic echinococcosis.Insights into imaging · 2022Review
- Characteristics and Clinical Course of Alveolar Echinococcosis in Patients with Immunosuppression-Associated Conditions: A Retrospective Cohort Study.Pathogens (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsBenzimidazoles are efficacious for treating non-resectable alveolar echinococcosis (AE), but their long-term parasitocidal (curative) effect is disputed. In this study, we prospectively analyzed the potential parasitocidal effect of benzimidazoles and whether normalization of FDG-PET/CT scans and anti-Emll/3-10-antibody levels could act as reliable "in vivo" parameters of AE-inactivation permitting to abrogate chemotherapy with a low risk for AE-recurrence.
methodThis prospective study included 34 patients with non-resectable AE subdivided into group A (n = 11), followed-up after diagnosis and begin of chemotherapy at months 6, 12 and 24, and group B (n = 23) with a medium duration of chemotherapy of 10 (range 2-25) years. All patients were assessed by FDG-PET/CT examinations and anti-EmII/3-10 serology. Chemotherapy was abrogated in patients with normalization of FDG-PET/CT and serum anti-EmII/3-10 levels. These patients were closely followed-up for AE recurrence. Endpoint (parasitocidal efficacy) was defined by the absence of AE-recurrence >24 months after stopping treatment.
resultsNormalization of FDG-PET/CT scan and anti-EmII/3-10 levels occurred in 11 of 34 patients (32%). After abrogation of chemotherapy in these 11 patients, there was no evidence of AE-recurrence within a median of 70.5 (range 16-82) months. However, the patients' immunocompetence appears pivotal for the described long-term parasitocidal effect of benzimidazoles.
conclusionsThe combination of negative FDG-PET/CT-scans and anti-EmII/3-10 antibody levels seem to be reliable parameters for assessing in vivo AE-larval inactivity after long-term benzimidazole chemotherapy.
trial registrationclinicaltrials.gov: NCT00658294.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.